PML INC
10QSB, EX-27, 2000-10-13
PHARMACEUTICAL PREPARATIONS
Previous: PML INC, 10QSB, 2000-10-13
Next: BARNES & NOBLE INC, 4, 2000-10-13



<TABLE> <S> <C>

<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                   May-31-2001
<PERIOD-END>                        Aug-31-2000
<CASH>                                        66,225
<SECURITIES>                                       0
<RECEIVABLES>                              1,839,751
<ALLOWANCES>                                  57,954
<INVENTORY>                                1,668,045
<CURRENT-ASSETS>                           3,912,079
<PP&E>                                     5,668,739
<DEPRECIATION>                             3,591,353
<TOTAL-ASSETS>                             6,024,939
<CURRENT-LIABILITIES>                      3,876,106
<BONDS>                                      844,007
                              0
                                  801,331
<COMMON>                                      19,970
<OTHER-SE>                                   348,525
<TOTAL-LIABILITY-AND-EQUITY>               6,024,939
<SALES>                                    3,240,530
<TOTAL-REVENUES>                           3,240,530
<CGS>                                      1,975,886
<TOTAL-COSTS>                              1,975,886
<OTHER-EXPENSES>                           1,144,175
<LOSS-PROVISION>                                   0
<INTEREST-EXPENSE>                            58,695
<INCOME-PRETAX>                               61,774
<INCOME-TAX>                                  22,914
<INCOME-CONTINUING>                           38,860
<DISCONTINUED>                                     0
<EXTRAORDINARY>                                    0
<CHANGES>                                          0
<NET-INCOME>                                  38,860
<EPS-BASIC>                                     0.01
<EPS-DILUTED>                                   0.01


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission